The Biotechnology Innovation Organization has issued a press release announcing the creation of essentially a US $1 billion fund to finance the development (particularly late stage) of antibiotics. The press release states:
Today more than 20 leading biopharmaceutical companies
announced the creation of an estimated $1 billion fund to help support the
pipeline for new antibiotic treatments. The AMR Action Fund was
launched as the threat of antimicrobial resistance, or AMR, continues to grow
and claim more lives. In response to today’s launch of the fund, BIO issued the
following statements celebrating the news:
“Antimicrobial resistance is one of the largest and looming
public health threats we face today,” said BIO President and CEO Dr.
Michelle McMurry-Heath. “Even as the world’s scientists work tirelessly to
fight COVID-19, we must not ease up on our battle against antimicrobial
resistance. Just as we’ve seen our industry step up during the pandemic, I
applaud these biopharmaceutical leaders and partners for committing to the
development of new antibiotics. The AMR Action Fund will provide critical
support for the development of new medicines, but it is up to policymakers to
enact the long-term changes needed to support healthy, sustainable markets for
the future development of new and effective antibiotics.”
“For years, we’ve watched
antimicrobial-resistance infections rapidly rise around the world, while the
market has slowly shrunk for new medicines to fight them,” said Greg Frank,
Director of Infectious Disease Policy at BIO & Director of the Working to
Fight AMR campaign. “Today’s new AMR Action Fund will have a tremendous
impact on the development of new antimicrobials, but we still need government
to implement new policies and incentives so companies can successfully develop,
test, and launch new antimicrobial products.”
Biopharmaceutical companies and foundations supporting the
fund are:
Almirall, Amgen, Bayer, Boehringer Ingelheim, Chugai, Daiichi
Sankyo, Eisai, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson,
LEO Pharma, Lundbeck, Menarini, Merck, MSD, Novartis, Novo Nordisk, Novo
Nordisk Foundation, Pfizer, Roche, Shionogi, Takeda, Teva, and UCB
For more details on the AMR Action Fund, visit www.AMRActionFund.com.
No comments:
Post a Comment